New therapy for chronic urticaria approved in Europe

Remibrutinib (Rhapsody) receives European market authorization for treating spontaneous chronic urticaria.

Published 23sem1 sourceNotableupdated 14sem
Lire en français
≈ 18s

The fact

This drug offers a new therapeutic option for patients with this disabling dermatological condition.

European approval should facilitate patient access to this innovation in the coming months.

Click the link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.
Follow topic →
Auto-synthesis from 1 media source · identified on June 11, 2026
← Back to home
Discover

Read more

All sante →